{
    "2019-09-23": [
        [
            {
                "time": "",
                "original_text": "议市厅丨复星医药业绩承压，上半年50亿销售费用侵蚀利润，“医药界PE”下一步该如何破局？ 盈利能力下降",
                "features": {
                    "keywords": [
                        "复星医药",
                        "业绩承压",
                        "销售费用",
                        "侵蚀利润",
                        "盈利能力下降"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "【中信建投医药|行业周报】新旧交替机会不断 配置高性价比标的",
                "features": {
                    "keywords": [
                        "中信建投",
                        "医药",
                        "行业周报",
                        "新旧交替",
                        "高性价比标的"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}